RAPT
Price:
$1.73
Market Cap:
$60.48M
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. The company's lead oncology drug candidate is FLX475, an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. It also focuses on the development o...[Read more]
Industry
Biotechnology
IPO Date
2019-10-31
Stock Exchange
NASDAQ
Ticker
RAPT
According to RAPT Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 27.70M. This represents a change of -91.65% compared to the average of 331.66M of the last 4 quarters.
The mean historical Enterprise Value of RAPT Therapeutics, Inc. over the last ten years is 579.62M. The current 27.70M Enterprise Value has changed 377.86% with respect to the historical average. Over the past ten years (40 quarters), RAPT's Enterprise Value was at its highest in in the December 2021 quarter at 1.06B. The Enterprise Value was at its lowest in in the September 2019 quarter at -37868023.00.
Average
579.62M
Median
525.43M
Minimum
249.12M
Maximum
982.02M
Discovering the peaks and valleys of RAPT Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 117.39%
Maximum Annual Enterprise Value = 982.02M
Minimum Annual Increase = -37.44%
Minimum Annual Enterprise Value = 249.12M
Year | Enterprise Value | Change |
---|---|---|
2023 | 912.13M | 48.47% |
2022 | 614.34M | -37.44% |
2021 | 982.02M | 117.39% |
2020 | 451.73M | -14.03% |
2019 | 525.43M | 62.88% |
2018 | 322.59M | 29.49% |
The current Enterprise Value of RAPT Therapeutics, Inc. (RAPT) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
836.16M
5-year avg
697.13M
10-year avg
579.62M
RAPT Therapeutics, Inc.’s Enterprise Value is greater than Connect Biopharma Holdings Limited (-54815984.00), less than Tyra Biosciences, Inc. (647.39M), greater than Xilio Therapeutics, Inc. (-2292216.00), less than Mineralys Therapeutics, Inc. (539.76M), less than Molecular Partners AG (107.67M), greater than AN2 Therapeutics, Inc. (7.13M), less than Pharvaris N.V. (672.07M), less than PepGen Inc. (108.11M), less than Monte Rosa Therapeutics, Inc. (351.25M), less than Design Therapeutics, Inc. (331.74M), greater than Werewolf Therapeutics, Inc. (-17421672.00), less than Ikena Oncology, Inc. (37.04M), less than Stoke Therapeutics, Inc. (451.87M), less than Anebulo Pharmaceuticals, Inc. (40.61M), less than PMV Pharmaceuticals, Inc. (40.53M), less than Eliem Therapeutics, Inc. (0), greater than HCW Biologics Inc. (26.86M), less than Relay Therapeutics, Inc. (605.49M), less than Pliant Therapeutics, Inc. (801.51M), less than Black Diamond Therapeutics, Inc. (123.50M), less than Arvinas, Inc. (1.20B),
Company | Enterprise Value | Market cap |
---|---|---|
-54815984.00 | $55.03M | |
647.39M | $744.96M | |
-2292216.00 | $50.55M | |
539.76M | $637.04M | |
107.67M | $195.74M | |
7.13M | $40.64M | |
672.07M | $1.02B | |
108.11M | $131.36M | |
351.25M | $433.13M | |
331.74M | $359.54M | |
-17421672.00 | $68.63M | |
37.04M | $73.83M | |
451.87M | $599.59M | |
40.61M | $42.01M | |
40.53M | $76.07M | |
0 | $342.68M | |
26.86M | $15.05M | |
605.49M | $708.03M | |
801.51M | $820.92M | |
123.50M | $123.92M | |
1.20B | $1.29B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like RAPT Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like RAPT Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is RAPT Therapeutics, Inc.'s Enterprise Value?
What is the highest Enterprise Value for RAPT Therapeutics, Inc. (RAPT)?
What is the 3-year average Enterprise Value for RAPT Therapeutics, Inc. (RAPT)?
What is the 5-year average Enterprise Value for RAPT Therapeutics, Inc. (RAPT)?
How does the current Enterprise Value for RAPT Therapeutics, Inc. (RAPT) compare to its historical average?